Viromed Medical Books First Profit but Revenue Miss and Strategic Reset Trigger 37% Selloff

Viromed posts €0.6M net profit but revenue of €5.1M falls short of €8-10M guidance, triggering a 37% stock drop to a 52-week low. Old 2026 forecast scrapped.

Viromed Medical finds itself in an unusual bind: the company has finally turned a corner on profitability, posting a net profit of €0.6 million for the 2025 financial year compared with a loss of €3.1 million a year earlier. Yet the share price has been hammered, falling more than 37% over seven days to close at €4.52 on Friday – a fresh 52-week low roughly 43% below the February high.

The contradiction is explained by the revenue side of the ledger. Sales climbed from €1.1 million to €5.1 million, a solid increase by any measure, but well short of management’s earlier projection of between €8 million and €10 million. The shortfall triggered a sharp re?rating as investors recalibrated their expectations for a growth stock that had promised much more.

Old guidance scrapped, new pivot under way

The revenue miss is directly linked to delays in the market launch of ViroCAP® and the regulatory approval of PulmoPlas®. As a result, the board has formally withdrawn its previous forecast for the 2026 financial year, which called for around €80 million in sales and a “clearly double?digit” EBIT margin. In its place, the company now only guides for a “significant increase” in both revenue and net income, declining to provide specific targets.

That shift from a concrete number to a vague ambition has unnerved the market, even as Viromed points to long?term drivers such as its cold?plasma technology and ongoing distribution partnerships. For now, the narrative leans heavily on pipeline execution rather than short?term delivery.

relyon acquisition adds another moving part

Alongside the financial reset, Viromed is pushing ahead with a major strategic move. In March it signed a letter of intent to acquire all shares of relyon plasma GmbH from TDK Electronics AG. The purchase price is in the low? to mid?double?digit million?euro range, and the deal is expected to close in the second quarter of 2026, subject to due diligence. relyon specialises in atmospheric plasma systems and would bring patented technology, manufacturing capacity, and research expertise under Viromed’s roof.

The acquisition is one of several steps designed to strengthen the company’s commercial footprint. Viromed is also working on a distribution agreement covering the United Arab Emirates, Qatar, Saudi Arabia and Kuwait, and is preparing to showcase its technology on more than 120 square metres of exhibition space at the EWMA 2026 conference.

Research partnerships and the next hard deadline

On the scientific front, Viromed continues to collaborate with the Hannover Medical School, the Helmholtz Centre for Infection Research and the University Hospital of Saarland on a range of studies. These academic ties support the broader case for its plasma?based wound?care products but are unlikely to influence the share price in the near term.

What will matter most is the audited annual report, due by 22 May 2026 at the latest. Until then all figures remain provisional, and the market will scrutinise the final accounts to see whether the preliminary profit holds and how management fleshes out its new, less?ambitious outlook. Without a concrete revenue target, the company’s credibility rests on turning delayed products into actual sales – and quickly.